Yesterday Redhill (NASDAQ:RDHL) announced an agreement with US-based medical food developer and manufacturer Entera Health for exclusive rights to market EnteraGam in the US. In exchange, RedHill will pay tiered royalties, but notably no upfront or milestone payments. EnteraGam is an FDA-regulated medical food intended for the dietary management of chronic diarrhea and has to be administered under medical supervision. This is the second product RedHill has added to its commercial portfolio after the co-promotion deal for Donnatal with Concordia Healthcare in January 2017.
Originally developed by Entera Health, EnteraGam was launched in 2013 and targeted diarrhoea-predominant irritable bowel syndrome (IBS-D) patients, although increasing data suggest it can be used for chronic diarrhoea due to various causes (RedHill will be able to market for all indications). EnteraGam is a serum-derived bovine immunoglobulin/protein isolate (SBI) with a proposed mechanism of action of restoring gut balance. RedHill already has one product, Bekinda (a once-daily oral formulation of ondansetron), for IBS-D in Phase II, although a drug with a different mechanism of action and therefore not a direct competitor. Instead, we see operational synergy as RedHill will gain experience and know-how in targeting IBS-D patients ahead of the launch of Bekinda, presuming supportive data.
To read the entire report Please click on the pdf File Below